<DOC>
	<DOCNO>NCT01652794</DOCNO>
	<brief_summary>The purpose phase I study determine high dose carboplatin gemcitabine ( gemcitabine hydrochloride ) give safely subject gynecologic cancer , combination stereotactic body radiation therapy ( SBRT ) . This dose call maximum tolerate dose ( MTD ) . To determine MTD , patient receive different amount carboplatin gemcitabine .</brief_summary>
	<brief_title>Carboplatin , Gemcitabine Hydrochloride , Stereotactic Body Radiation Therapy Gynecological Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate carboplatin/gemcitabine dose administer SBRT measure &lt; 30‐day acute toxicity define Common Terminology Criteria Adverse Events ( CTCAE ) v4.0 . SECONDARY OBJECTIVES : I. Off-study SBRT target local control assessment : 6-week post-trial fludeoxyglucose F 18 ( 18F-FDG ) positron emission tomography ( PET ) /computed tomography ( CT ) image response European Organisation Research Treatment Cancer ( EORTC ) PET criterion list National Cancer Institute ( NCI ) guideline . II . Off-treatment late toxicity assessment : record 3-month 6-month radiation-related toxicity define CTCAE v4.0 . III . Off‐study global clinical benefit assessment : 6‐month post-therapy clinical benefit ( defined percentage patient complete , partial , stable disease least 6 month ) . TERTIARY OBJECTIVES : I . Associate pretherapy tumor biopsy ribonucleotide reductase ( R1 , R2 , p53R2 ) , Tip60 Poly ( ADP‐ribose ) polymerase 1/2 expression 6‐week therapy response . OUTLINE : This dose-escalation study carboplatin gemcitabine hydrochloride . Patients also receive carboplatin intravenously ( IV ) 30 minute gemcitabine hydrochloride IV 30 minute day 1 undergo SBRT day 2-4 . After completion study treatment , patient follow every 3 month 2 year , every 6 month 1 year , yearly 2 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Germinoma</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<mesh_term>Pseudomyxoma Peritonei</mesh_term>
	<mesh_term>Leydig Cell Tumor</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patient diagnosis persistent recurrent gynecologic cancer Patient age &gt; 18 year . Patient must least one abdominopelvic measurable site disease define 9.1.3 ; . A treatment plan 18F‐FDG positron emission tomography compute tomography scan ( PET/CT ; whole body ) may use complement assessment , &amp; do must complete prior first dose carboplatin / gemcitabine within 35 day first day SBRT . There MUST BE four ( 4 ) intend radiosurgical target lesion . An individual ( one four ) radiosurgical target lesion MUST NOT EXCEED volume great 160 cubic centimeter ( cc ) . No prior cryosurgery radiofrequency ablation SBRT‐target lesion . Patients prior cryoablation radiofrequency ablation exclude treatment design destroy tissue freeze heat . Radiation treatment give SBRT may work biologically may cause excessive tissue injury patient prior cryoablation radiofrequency ablation . Patient major medical illness psychiatric illness : 1 . New York Heart Association ( NYHA ) class 3 4 congestive heart failure ; 2. unstable angina pectoris ; 3. symptomatic cardiac arrhythmia ; 4. hypertension diastolic blood pressure great 110 mmHg ; 5. pulmonary disease consist dyspnea rest require oxygen supplementation ; 6. renal function impairment ( defined baseline serum creatinine &gt; 2.0 mg/dL ) ; 7. psychiatric illness/social situation would limit compliance . Patient must know brain metastasis . These patient exclude clinical trial poor prognosis often develop progressive neurological dysfunction would confound neurological adverse event evaluation . Patient must demonstrate adequate organ function ( &lt; 35 day enrollment ) : Bone marrow : absolute neutrophil count ( ANC ) ≥ 1500/mcl , platelet ≥ 100,000 , hemoglobin ≥ 10 mg/dL . Renal function : creatinine ≤ 2.0 mg/dL . Hepatic function : bilirubin ≤ 1.5X institutional upper limit normal ( ULN ) ; AST , ALT , alkaline phosphatase ≤ 2.5X ULN Patient MUST prior chemotherapy radiation gynecologic cancer . Patient &gt; 28 day previous treatment ( chemotherapy radiation ) toxicity relate previous treatment must resolve grade 1 baseline . Patient Gynecologic Oncology Group performance status score 0 1 . Patient able give study‐specific inform consent Any patient NOT meet criterion Any patient active connective tissue disease lupus dermatomyositis exclude ; patient active connective tissue disease excessive risk organ function‐impairing fibrosis Any patient active Crohn 's disease active ulcerative colitis exclude ; patient condition excessive risk organ function‐impairing fibrosis Any patient know anaphylaxis carboplatin gemcitabine exclude Pregnant woman exclude study radiation potential teratogenic abortifacient effect ; screen beta‐human chorionic gonadotropin ( hcg ) level ( urine blood ) diagnostic test use determine eligibility woman childbearing potential ; woman child‐bearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately ; potential risk may also apply carboplatin/gemcitabine chemotherapy agent use study Human immunodeficiency virus ( HIV ) ‐positive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction carboplatin gemcitabine ; addition , patient know HIV‐positive patient exclude due increase risk lethal infection treat marrow‐suppressive therapy carboplatin/gemcitabine ; HIV test mandatory eligibility evaluation Due perceive increase risk transplant organ lethal dysfunction lethal infection , patient visceral organ transplant eligible Patients active non‐gynecologic invasive malignancy exclude ; patient invasive malignancy ( ) cancer present within last two year exclude</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>